PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that pre-clinical development of a second siRNA oncology therapeutic, CALAA-02, is underway. The intracellular target for CALAA-02 is HIF-2alpha, or Hypoxia Inducible Factor-2 alpha. HIF-2alpha is overexpressed in a number of solid tumors and is critical for many aspects of tumorigenesis, such as metastasis, angiogenesis, tumor cell proliferation, and tumor response to radiation. HIF-2alpha has been difficult to target using traditional drugs but is effectively targeted by the proprietary siRNA in CALAA-02.
